Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental asthma drug briquilimab fails to reach Late-Stage testing

NCT ID NCT06592768

Disease control Sponsor: Jasper Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This Phase 1 trial tested a single dose of briquilimab in 17 adults with mild-to-moderate allergic asthma to see if it was safe and could reduce asthma attacks triggered by allergens. The study was terminated early, meaning it did not continue as planned. The main goal was to check for side effects and measure lung function after an allergen challenge.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
briquilimab (also called JSP191)
What this could lead to
If successful, this could point toward a new treatment option for allergic asthma by targeting the underlying immune response.
What could go wrong
This was a very early, small Phase 1 trial that was terminated, so results are limited. The drug may not prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

17 people

The number who actually took part.

Started

Nov 2024

Finished

Aug 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men and women 18 to 65 years of age; stable, allergic asthma; history of episodic wheeze and shortness of breath; forced expiratory volume in 1 second (FEV1) at baseline at least 70% of the predicted value; able to comprehend and follow all required study procedures; willing and able to sign an informed consent form; positive methacholine challenge at baseline (concentration of methacholine causing 20% decrease in FEV1 \[PC20\] PC20 ≤ 16 mg/mL or PD20 equivalent to ≤400µg); and positive skin-prick test and positive allergen-induced early and late airway bronchoconstriction to common aeroallergens. Exclusion Criteria: * Worsening of asthma or respiratory infection in the preceding 6 weeks; lung disease other than allergic asthma; prior treatment with a c-Kit inhibiting therapy; anaphylaxis to any parenterally administered biologics; use of asthma medications (note: intermittent doses of short-acting β2-agonist are allowed once weekly for relief of symptoms but prophylactic use for exercise is allowed as-needed); pregnant or lactating women; and women actively seeking pregnancy or who are not using adequate contraception.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Allergic asthma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

allergic asthma allergic disease asthma bronchial disorder Chronic Disease Hypersensitivity, Immediate immune system disorder lung disorder obstructive lung disease Respiratory Hypersensitivity respiratory system disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Allergic asthma

Contacts and locations

Locations

  • McMaster University

    Hamilton, Ontario, L8N 3Z5, Canada

  • University of Alberta

    Edmonton, Alberta, T6G 2R3, Canada

  • University of British Columbia

    Vancouver, British Columbia, V6T 1Z4, Canada

  • University of Calgary

    Calgary, Alberta, T2N 1N4, Canada

  • University of Laval

    Québec, Quebec, G1V 0A6, Canada

  • University of Saskatchewan

    Saskatoon, Saskatchewan, S7N 5A2, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.